CHCWM – Cancer & Hematology Centers of West Michigan

BDB018-101 (Seven and Eight Biopharmaceuticals Inc.)

Description:  A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Mechanism of Action:  TLR7/8 dual agonist (a novel immunotherapy target).

Target Patient Population:  All solid tumors. 

Study Design:  Drug is administered IV weekly in a 21 day cycle